Drug Type Small molecule drug |
Synonyms (2-(6-(2-(4-cyclopropylpyrimidin-5-yl)-4-fluorophenoxy)-1,2,4-triazin-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)((1S,3aR,6aS)-octahydrocyclopenta[c]pyrrol-1-yl)methanone, BN104 |
Target |
Mechanism menin inhibitors(Menin inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
RegulationFast Track (US), Orphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
acute leukemia | Phase 2 | CN | 16 Oct 2023 | |
Adult Acute Lymphocytic Leukemia | Phase 2 | CN | 16 Sep 2023 | |
Adult Acute Myeloblastic Leukemia | Phase 2 | CN | 16 Sep 2023 | |
Recurrent Acute Leukemia | IND Approval | US | 21 Sep 2023 | |
Refractory Acute Leukemia | IND Approval | US | 21 Sep 2023 | |
Acute Myeloid Leukemia | Preclinical | US | 17 Apr 2023 |